Valuation: ABVC BioPharma, Inc.

Market Cap 2.6Cr 2.33Cr 2.14Cr 1.94Cr 3.62Cr 246.53Cr 3.69Cr 26Cr 10Cr 129.68Cr 9.74Cr 9.54Cr 408.97Cr P/E 2024
-1.4x
P/E 2025 -5.42x
Enterprise Value 2.87Cr 2.57Cr 2.36Cr 2.14Cr 4Cr 272.42Cr 4.08Cr 28Cr 11Cr 143.3Cr 11Cr 11Cr 451.93Cr EV / Sales 2024
19.8x
EV / Sales 2025 -
Free-Float
79.73%
Yield 2024 *
-
Yield 2025 -
1 day-3.85%
1 week-4.52%
Current month-5.66%
1 month-3.85%
3 months-0.99%
6 months-2.91%
Current year-53.05%
1 week 1
Extreme 1
1.11
1 month 0.89
Extreme 0.8918
1.11
Current year 0.71
Extreme 0.7069
2.43
1 year 0.71
Extreme 0.7069
3.06
3 years 0.4
Extreme 0.4
5.48
5 years 0.4
Extreme 0.4
116.9
10 years 0.4
Extreme 0.4
378
Manager TitleAgeSince
Chief Executive Officer 40 21/06/2023
Chief Tech/Sci/R&D Officer 72 15/06/2023
Director TitleAgeSince
Chairman 39 01/07/2015
Director/Board Member 65 23/11/2017
Director/Board Member 55 23/11/2017
Date Insider Type Main position Quantity % Market Cap. Importance
20/05/22 Other

Chairman

79,08,805 26.0954%
02/08/21 Other

Director

5,949 0.0243%
02/08/21 Other

Chief Executive Officer

18,404 0.0752%
Change 5-day change 1-year change 3-year change Capi.($)
-3.85%-4.52%-63.90%-27.54% 2.7Cr
-0.62%+0.50%+33.92%+60.07% 6.44TCr
+0.35%+3.04%+12.64%+83.62% 5.62TCr
+0.53%+2.55%+13.90%+104.77% 5.42TCr
-2.81%-3.95%+22.72%+48.57% 4.53TCr
-0.33%-3.12%+17.62%+117.27% 4.22TCr
+0.55%+1.93%+229.73%+928.00% 4.08TCr
+3.27%+47.40%+110.44%+94.92% 3.38TCr
+1.22%-1.39%+13.92%+46.95% 3.22TCr
-1.29%-1.72%+21.00%-6.85% 2.36TCr
Average -0.30%+4.18%+41.20%+144.98% 3.93TCr
Weighted average by Cap. +0.02%+3.64%+49.57%+162.46%

Financials

2024 2025
Net sales 5L 5L 4L 4L 7L 4.84Cr 7L 50.06L 20.1L 2.55Cr 19.12L 18.72L 8.03Cr -
Net income -49.03L -43.91L -40.39L -36.6L -68.41L -47Cr -69.69L -4.82Cr -1.93Cr -24Cr -1.84Cr -1.8Cr -77Cr -79.09L -70.83L -65.15L -59.03L -1.1Cr -75Cr -1.12Cr -7.77Cr -3.12Cr -40Cr -2.97Cr -2.9Cr -124.57Cr
Net Debt 28.82L 25.81L 23.74L 21.51L 40.21L 27Cr 40.97L 2.83Cr 1.14Cr 14Cr 1.08Cr 1.06Cr 45Cr 27.27L 24.43L 22.47L 20.36L 38.05L 26Cr 38.77L 2.68Cr 1.08Cr 14Cr 1.02Cr 1Cr 43Cr
Projected Income Statement - Annual - ABVC BioPharma, Inc.
Logo ABVC BioPharma, Inc.
ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer.
Employees
-
Date Price Change Volume
30/26/30 $1.000 -3.85% 20,010
29/26/29 $1.040 -4.59% 34,879
28/26/28 $1.090 +3.81% 35,408
27/26/27 $1.050 0.00% 24,225
26/26/26 $1.050 +0.96% 36,596
  1. Stock Market
  2. Stocks
  3. ABVC Stock